Apolipoproteins: New players in cancers
Authors:
Open Access
- 25 November 2022
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 1051280
Abstract
Apolipoproteins (APOs), the primary protein moiety of lipoproteins, are known for their crucial role in lipid traffic and metabolism. Despite extensive exploration of APOs in cardiovascular diseases, their roles in cancers did not attract enough attention. Recently, research focusing on the roles of APOs in cancers has flourished. Multiple studies demonstrate the interaction of APOs with classical pathways of tumorigenesis. Besides, the dysregulation of APOs may indicate cancer occurrence and progression, thus serving as potential biomarkers for cancer patients. Herein, we summarize the mechanisms of APOs involved in the development of various cancers, their applications as cancer biomarkers and their genetic polymorphism associated with cancer risk. Additionally, we also discuss the potential anti-cancer therapies by virtue of APOs. The comprehensive review of APOs in cancers may advance the understanding of the roles of APOs in cancers and their potential mechanisms. We hope that it will provide novel clues and new therapeutic strategies for cancers.Keywords
This publication has 195 references indexed in Scilit:
- Apolipoprotein E gene polymorphism influences aggressive behavior in prostate cancer cells by deregulating cholesterol homeostasisInternational Journal of Oncology, 2013
- The diagnostic value of apolipoprotein E in malignant pleural effusion associated with non-small cell lung cancerClinica Chimica Acta, 2013
- Expression and clinical significance of complement C3, complement C4b1 and apolipoprotein E in pancreatic cancerOncology Letters, 2013
- A case–control study on the effect of Apolipoprotein E genotypes on gastric cancer risk and progressionBMC Cancer, 2012
- Apolipoprotein E (APOE) Polymorphisms and Susceptibility to Breast Cancer: A Meta-AnalysisCancer Research and Treatment, 2012
- The targeted intracellular delivery of cytochrome C protein to tumors using lipid-apolipoprotein nanoparticlesBiomaterials, 2012
- Functionalization with ApoE-derived peptides enhances the interaction with brain capillary endothelial cells of nanoliposomes binding amyloid-beta peptideJournal of Biotechnology, 2011
- D‐4F, an apoA‐I mimetic peptide, inhibits proliferation and tumorigenicity of epithelial ovarian cancer cells by upregulating the antioxidant enzyme MnSODInternational Journal of Cancer, 2011
- Serum Apolipoproteins C-I and C-III Are Reduced in Stomach Cancer Patients: Results from MALDI-Based Peptidome and Immuno-Based Clinical AssaysPLOS ONE, 2011
- L-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGF/basic FGF signaling pathwaysIntegrative Biology, 2011